A SMART Platform for Scalable Biotherapeutic Development: cDNA to 200L Single-Use Stirred-Tank Bioreactor
Posted on May 25, 2020
Establishing a platform for developing and manufacturing therapeutic proteins will eliminate the bottleneck between cell-line development and tech transfer. The Celltheon SMARTTM Technology Platform in combination with Pall Biotech’s manufacturing equipment accelerates time from cDNA to pilot scale with a pre-defined fed-batch and downstream processing platform for monoclonal antibodies and difficult to express therapeutic proteins. In this case study, Celltheon demonstrates a workflow established to develop an RCB followed by scale-up and reproducible product quality from bench to pilot scale in the 200L Allegro STR single-use bioreactor.
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
